Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients

Melissa Corson; Ashley Moch; Sammy Saab

Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients

Gastroenterol Hepatol (N Y). 2018 May;14(5):280-285.

Authors

Melissa Corson¹, Ashley Moch¹, Sammy Saab¹

Affiliation

¹ Dr Corson is a medical resident in the Department of Medicine at the University of California at Los Angeles in Los Angeles, California. Ms Moch is a research assistant in the Department of Surgery at the University of California at Los Angeles. Dr Saab is a professor in the Departments of Medicine and Surgery at the University of California at Los Angeles.

PMID: 29991935
PMCID: PMC6034610

Abstract

An important interplay exists between hepatitis C virus (HCV) infection and chronic kidney disease (CKD). HCV infection is associated with an increased risk of morbidity and mortality in patients coinfected with CKD, and patients with CKD have an increased risk of HCV infection. Direct-acting antiviral (DAA) agents have changed the landscape of treatment with excellent sustained virologic response rates and fewer side effects than previously seen. An increasing number of studies demonstrate that DAA agents are efficacious and safe both in patients on dialysis and in patients who have undergone kidney transplantation. This article reviews the current literature on approved DAA agents for the treatment of HCV infection in patients on dialysis and in kidney transplant recipients.

Keywords: Hepatitis C virus; chronic kidney disease; direct-acting antiviral agents; kidney transplant.